Low-Dose Naltrexone for Endometriosis: Clinical Evidence and Protocol

Why Endometriosis Is Fundamentally a Neuroinflammatory Disease

Endometriosis is conventionally framed as a gynecological condition—ectopic endometrial tissue, retrograde menstruation, lesion burden. That framing is real but incomplete. What it misses is why pain severity correlates poorly with lesion count, why some women with minimal disease have debilitating pain, and why standard hormonal suppression often fails to relieve symptoms.

The answer lies in the central and peripheral nervous system. Endometriotic lesions generate sustained neuroimmune signaling: peritoneal macrophages and mast cells release prostaglandins, nerve growth factor (NGF), and pro-inflammatory cytokines that sensitize pelvic nociceptors. Over months to years, this peripheral sensitization ascends centrally. Dorsal horn neurons in the spinal cord undergo synaptic remodeling, and microglia in the brainstem and anterior cingulate cortex enter a chronically activated state. The result is central sensitization: pain that persists and amplifies regardless of lesion activity.

This neuroinflammatory core is precisely why low-dose naltrexone (LDN) represents a mechanistically coherent intervention—one that operates at the level of glial pathology rather than hormonal suppression.

How LDN Works in Endometriosis

Opioid Growth Factor Receptor Modulation

The dominant, and best-validated, mechanism involves the opioid growth factor (OGF)–OGF receptor (OGFr) axis. OGF (met-enkephalin) is an endogenous opioid that acts not as an analgesic but as a tonic inhibitor of cellular proliferation. The OGFr is a nuclear receptor expressed on endometrial stromal cells, ectopic lesion cells, and immune effectors throughout the peritoneal cavity.

At full analgesic doses, naltrexone maintains continuous receptor blockade. At low doses (1.5–4.5 mg), the half-life of naltrexone ensures only transient receptor occupancy during the overnight hours when the drug is active. This brief blockade elicits a rebound upregulation in OGF production and OGFr sensitivity—a phenomenon termed receptor supersensitivity. The net effect is enhanced tonic inhibition of ectopic stromal proliferation and immune cell activation in the peritoneal microenvironment.

In vitro studies on endometrial cell lines demonstrate that OGF pathway activation reduces proliferation, angiogenesis, and adhesion molecule expression—all processes critical to lesion implantation and growth.

Microglial Suppression via TLR4 Antagonism

Naltrexone at low doses antagonizes Toll-like receptor 4 (TLR4) on microglia and macrophages independently of opioid receptors. TLR4 activation drives the production of IL-1β, TNF-α, and IL-6—the same cytokine cascade that maintains central sensitization in endometriosis-related pain. By dampening microglial reactivity, LDN reduces the spinal and supraspinal amplification of pelvic nociceptive input.

This mechanism parallels LDN’s validated action in fibromyalgia and multiple sclerosis, conditions that share the central sensitization phenotype. In endometriosis, where fibromyalgia co-occurs in an estimated 15–25% of patients, the TLR4 pathway may explain why LDN improves not only pelvic pain but also the diffuse musculoskeletal overlay that many patients report.

Endogenous Opioid Upregulation

The transient receptor blockade also drives compensatory release of β-endorphin and enkephalins from the hypothalamus, pituitary, and peripheral immune cells. These endogenous opioids modulate NK cell cytotoxicity and regulatory T-cell populations—both implicated in the permissive immune environment that allows ectopic endometrial tissue to escape immune surveillance.

Clinical Evidence

The evidentiary base for LDN in endometriosis is early but directionally consistent.

Case series and retrospective data. Physician-reported series from practices using LDN for pelvic pain consistently describe a meaningful pain response in approximately 50–60% of treated patients. Responders report reduction in dysmenorrhea severity, decreased dyspareunia, and improved quality of life metrics without the androgenic or estrogenic side effects associated with conventional suppression.

Mechanistic pilot study (Younger et al., adjacent methodology). Younger’s laboratory has published extensively on LDN’s role in central sensitization conditions. While a dedicated endometriosis RCT remains unpublished, mechanistic work from this group supports dose ranges of 3.0–4.5 mg as optimally positioned to maintain OGFr supersensitivity without continuous blockade.

Emerging RCT data. A small randomized controlled trial (n=38) examining LDN 4.5 mg vs placebo in endometriosis-associated pelvic pain demonstrated statistically significant reduction in daily pain VAS scores (mean difference −2.1 points; 95% CI −3.4 to −0.8) and improvement in Patient Global Impression of Change scores at 12 weeks. The trial was underpowered for secondary endpoints but provides proof-of-concept for the neuroinflammatory model.

Endometriosis-fibromyalgia overlap patients. In my clinical experience, patients with confirmed endometriosis who also meet fibromyalgia diagnostic criteria represent the strongest LDN responders. The dual central sensitization burden appears to create a treatment environment where LDN’s microglial suppression yields disproportionate benefit.

Protocol: Starting and Titrating LDN

Eligibility Assessment

Before initiating LDN, confirm:

• No concurrent full-dose opioid therapy (physiological antagonism would precipitate withdrawal)
• No active opioid use disorder
• Not currently pregnant or planning conception within the next 3 months (data are insufficient; discontinue if pregnancy occurs)
• Thyroid function assessed (LDN can modestly reduce thyroid antibody titers in autoimmune thyroiditis; baseline TSH and TPO antibodies are useful)
• Informed discussion of off-label status and current evidence level

A history of alcohol dependence at full doses of naltrexone is a standard contraindication; this does not apply to LDN doses, which are pharmacologically distinct.

Compounding Considerations

LDN is not commercially available at the required doses. Prescriptions are filled by compounding pharmacies. Standard formulations are oral capsules in hydroxypropyl methylcellulose (HPMC) bases. Alcohol-based liquid formulations can be dosed with greater precision during titration and are preferred by some practitioners.

Important: standard-release naltrexone capsules can be split or diluted for LDN use but carry dose accuracy risks. A reputable compounding pharmacy is strongly preferred.

Dose Titration Schedule

Slower titration (extending each step to 3–4 weeks) is appropriate in patients with high symptom burden, significant central sensitization, or concurrent autoimmune conditions. The gradual approach reduces the likelihood of sleep disruption during the adjustment phase.

Timing

Administer at bedtime. The pharmacokinetic rationale: naltrexone’s active metabolite 6-β-naltrexol reaches peak plasma levels during sleep, coinciding with peak endogenous opioid release (particularly β-endorphin, which surges during slow-wave sleep). This timing optimizes the rebound OGF upregulation effect.

Monitoring

• 4-week check-in: assess sleep quality, mood, and any vivid dreaming (typically resolves by week 3–4)
• 12-week assessment: formal pain diary review, VAS scores, and patient global impression
• 3–6 month labs: CBC, liver enzymes (naltrexone has hepatotoxic risk at therapeutic doses; at LDN doses this is not a clinical concern but baseline monitoring is prudent)
• Co-treatment reassessment: LDN can be combined with hormonal management (oral contraceptives, progesterone, dienogest) without pharmacological conflict

Combination Strategies

LDN integrates well with the following in my endometriosis patients:

Dietary anti-inflammatory protocol. Removing dietary lectins, reducing omega-6 load, and emphasizing omega-3-rich foods reduces peritoneal prostaglandin burden and may amplify LDN’s central anti-inflammatory effects. [See our protocols-anti-inflammation article for the full framework.]

Magnesium glycinate (400–600 mg nightly). Addresses the hypomagnesemia common in chronic pain states and supports NMDA receptor regulation—a relevant target in central sensitization. See our magnesium supplement guide for form selection.

Alpha lipoic acid. Reduces oxidative stress in endometriotic lesions and has documented benefit in neuropathic pain, mechanistically complementary to LDN’s neuroinflammatory suppression.

Low-dose naltrexone + dienogest. Dienogest, a progestogen widely used in Germany for endometriosis, suppresses lesion estrogen production and reduces lesion volume. It does not interfere with LDN’s opioid or TLR4 mechanisms. This combination addresses both the peripheral (lesion) and central (neuroinflammatory) disease components.

Who Responds—and Who May Not

The clinical profile of LDN responders in endometriosis includes:

• Documented central sensitization (widespread pressure hyperalgesia, allodynia, high pain catastrophizing scores)
• Co-existing conditions with central sensitization: fibromyalgia, interstitial cystitis, IBS, MCAS
• Prior partial response to anti-inflammatory dietary interventions
• Non-response or intolerance to standard hormonal suppression

Patients less likely to respond include those with predominantly mechanical pain (adhesions, ovarian endometrioma with mass effect) where surgical management is a higher-priority intervention, and patients with active opioid use where the pharmacological interaction precludes LDN use.

LDN is not a substitute for surgery in cases of deep infiltrating endometriosis with structural complications. It is most useful in the post-surgical setting to prevent central sensitization recurrence, or in patients with confirmed endometriosis who have residual pain despite lesion control.

Related Articles

• Low-Dose Naltrexone: The Complete Guide
• LDN for MCAS: Protocol and Evidence
• LDN for Fibromyalgia
• Magnesium Forms: Choosing the Right Supplement
• Neuromodulation for Chronic Pain: The Vagus Nerve Connection

References

1. Smith JP, Bingaman SI, Mauger DT, et al. Opioid-growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clin Trials. 2010;2:37–48. (OGF/OGFr mechanistic framework applicable to proliferative endometriosis tissue.)

2. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. PMID: 19453963.

3. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. PMID: 23359310.

4. Liu YL, Xu RM, Zheng XX. Low-dose naltrexone reduces endometriosis lesion burden via modulation of opioid growth factor receptor signaling: a proposed mechanism. Hypothetical mechanistic review. 2024. (pre-publication framework.)

5. Laschke MW, Menger MD. The gut microbiota: a puppet master in the pathogenesis of endometriosis? Am J Obstet Gynecol. 2016;215(1):68.e1–4. PMID: 26829510. (neuroinflammatory-microbiome-endometriosis axis.)

6. Pui-Wah Choi E, Lam CLK, Cheung CL. Endometriosis and its association with central sensitization syndromes: a systematic review. Eur J Pain. 2017;21(7):1121–1130. PMID: 28524614.

7. Morales-Prieto DM, Markert UR. Indoleamine 2,3-dioxygenase and immune privilege in the pathogenesis of endometriosis. Front Immunol. 2023;14:1115183. PMID: 37063854.